TRAVERE THERAPEUTICS, INC. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
TRAVERE THERAPEUTICS, INC. (TVTX) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of $9.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-04
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $30.09M, a 2149.18% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$20.90M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $17.34M, a 124.22% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $19.70M, a 728.47% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $28.84M.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was -$31.06M, a 239.16% decline from fiscal 2023.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $22.32M, a 0.63% increase from fiscal 2022.
- TRAVERE THERAPEUTICS, INC. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $22.18M, a 33.00% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month as first filed | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $30.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $9.19M 10-Q · filed 2026-08-04 | $26.53M derived: sum of 3 quarters · filed 2026-08-04 | $46.23M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | -$20.90M 10-Q · filed 2026-05-04 | -$3.56M derived: sum of 2 quarters · filed 2026-05-04 | $16.14M derived: sum of 3 quarters · filed 2026-05-04 | $17.48M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $17.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $37.04M derived: sum of 2 quarters · filed 2026-02-19 | $38.38M derived: sum of 3 quarters · filed 2026-08-04 | $28.84M 10-K · filed 2026-02-19 | ||||
| 2025-09-30 | $19.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $21.04M derived: sum of 2 quarters · filed 2026-08-04 | $11.50M 10-Q · filed 2025-10-30 | $19.23M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $1.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$8.20M 10-Q · filed 2026-08-04 | -$467.00K derived: sum of 3 quarters · filed 2026-08-04 | $1.91M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$9.54M 10-Q · filed 2026-05-04 | -$1.80M derived: sum of 2 quarters · filed 2026-05-04 | $573.00K derived: sum of 3 quarters · filed 2026-05-04 | -$62.07M derived: sum of 4 quarters · filed 2026-05-04 | ||||
| 2024-12-31 | $7.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $10.11M derived: sum of 2 quarters · filed 2026-02-19 | -$52.53M derived: sum of 3 quarters · filed 2026-02-19 | -$31.06M 10-K · filed 2026-02-19 | ||||
| 2024-09-30 | $2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$60.27M derived: sum of 2 quarters · filed 2025-10-30 | -$38.79M 10-Q · filed 2025-10-30 | -$12.57M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-06-30 | -$62.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$41.17M 10-Q · filed 2025-08-06 | -$14.95M derived: sum of 3 quarters · filed 2026-02-19 | -$11.55M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2024-03-31 | $21.47M 10-Q · filed 2025-05-01 | $47.70M derived: sum of 2 quarters · filed 2026-02-19 | $51.10M derived: sum of 3 quarters · filed 2026-02-19 | $52.67M derived: sum of 4 quarters · filed 2026-02-19 | ||||
| 2023-12-31 | $26.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $29.63M derived: sum of 2 quarters · filed 2026-02-19 | $31.20M derived: sum of 3 quarters · filed 2026-02-19 | $22.32M 10-K · filed 2026-02-19 | ||||
| 2023-09-30 | $3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $4.98M derived: sum of 2 quarters · filed 2024-10-31 | -$3.90M 10-Q · filed 2024-10-31 | $2.27M derived: sum of 4 quarters · filed 2025-02-21 | ||||
| 2023-06-30 | $1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$7.30M 10-Q · filed 2024-08-01 | -$7.90M 10-Q · filed 2023-08-03 | -$1.13M derived: sum of 3 quarters · filed 2025-02-21 | $5.81M derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2023-03-31 | -$8.88M 10-Q · filed 2024-05-06 | -$9.61M 10-Q · filed 2023-05-04 | -$2.71M derived: sum of 2 quarters · filed 2025-02-21 | $4.23M derived: sum of 3 quarters · filed 2025-02-21 | $17.71M derived: sum of 4 quarters · filed 2025-02-21 | |||
| 2022-12-31 | $6.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $13.11M derived: sum of 2 quarters · filed 2025-02-21 | $26.59M derived: sum of 3 quarters · filed 2025-02-21 | $22.18M 10-K · filed 2025-02-21 | $22.26M 10-K · filed 2023-02-23 | |||
| 2022-09-30 | $6.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $20.42M derived: sum of 2 quarters · filed 2023-11-07 | $16.01M 10-Q · filed 2023-11-07 | $15.23M 10-Q · filed 2022-10-27 | $26.45M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-06-30 | $13.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $9.07M 10-Q · filed 2023-08-03 | $19.52M derived: sum of 3 quarters · filed 2024-02-20 | $20.43M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | -$4.41M 10-Q · filed 2023-05-04 | $6.03M derived: sum of 2 quarters · filed 2024-02-20 | $6.95M derived: sum of 3 quarters · filed 2024-02-20 | $21.75M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $10.45M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $11.37M derived: sum of 2 quarters · filed 2024-02-20 | $26.16M derived: sum of 3 quarters · filed 2024-02-20 | $16.68M 10-K · filed 2024-02-20 | $18.31M 10-K · filed 2023-02-23 | |||
| 2021-09-30 | $920.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-27 | $15.72M derived: sum of 2 quarters · filed 2022-10-27 | $6.23M 10-Q · filed 2022-10-27 | |||||
| 2021-06-30 | $14.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $5.31M 10-Q · filed 2022-08-04 | ||||||
| 2021-03-31 | -$9.49M 10-Q · filed 2022-05-05 | |||||||
| 2020-12-31 | $4.42M 10-K · filed 2023-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |